(1-甲基-4-苯基-哌啶-4-基)-甲醇 | 4220-10-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: (1-甲基-4-苯基-哌啶-4-基)-甲醇
• 英文名称: 1-Methyl-4-hydroxymethyl-4-phenylpiperidin
• 英文别名: 4-Phenyl-4-hydroxymethyl-1-methylpiperidin；4-Hydroxymethyl-1-methyl-4-phenylpiperidin；(1-methyl-4-phenyl-piperidin-4-yl)-methanol；(1-Methyl-4-phenyl-[4]piperidyl)-methanol；1-N-methyl-4-hydroxymethy-4-phenylpiperidine；4-hydroxymethyl-1-methyl-4-phenylpiperidine；4-Piperidinemethanol, 1-methyl-4-phenyl-；(1-methyl-4-phenylpiperidin-4-yl)methanol
• CAS: 4220-10-4
• 化学式: C₁₃H₁₉NO
• 分子量: 205.3
• InChiKey: FDIJINBEVKPNEC-UHFFFAOYSA-N

物化性质

• 熔点：
  136.8-137.4 °C
• 沸点：
  314.3±35.0 °C(Predicted)
• 密度：
  1.033±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  (1-甲基-4-苯基-哌啶-4-基)-甲醇 在 sodium carbonate 作用下， 以 四氢呋喃 为溶剂， 生成 (1-methyl-4-phenylpiperidin-4-yl)methyl N-[2-(3,4-dimethoxyphenyl)ethyl]carbamate
  参考文献：
  名称：

  Muscarinic acetylcholine receptor binding affinities of pethidine analogs

  摘要：

  A series of pethidine analogs were synthesized and their affinities for the [H-3]N-methyl-scopolamine (NMS) binding site on muscarinic acetylcholine receptors (mAChRs) were determined using M-1, M-3 or M-5 human mAChRs expressed by Chinese hamster ovary (CHO) cell membranes. Compound 6b showed the highest binding affinities at M-1, M-3 and M-5 mAChRs (K-i = 0.67, 0.37, and 0.38 mu M, respectively). (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.10.029
• 作为产物：
  描述：

  哌替啶 在 sodium 、 丁二醇 作用下， 生成 (1-甲基-4-苯基-哌啶-4-基)-甲醇
  参考文献：
  名称：

  Basic Ethers of Some Piperidine Alcohols

  摘要：

  DOI：

  10.1021/ja01630a077
• 作为试剂：
  描述：

  哌替啶 、 diisobutylaluminum hydride 、 甲醇 、 乙醚 在 氮气 、 diisobutylaluminum hydride 、 水 、 Sodium sulfate-III 、 (1-甲基-4-苯基-哌啶-4-基)-甲醇 、 title compound 作用下， 以 甲苯 为溶剂， 反应 2.0h， 生成 1-甲基-4-苯基-哌啶-4-甲醛
  参考文献：
  名称：

  4-phenylpiperidine compounds and their use

  摘要：

  具有以下式子的吡啶化合物##STR1##其中R.sup.1是氢，(C.sub.1-6 -烷氧基芳基)烷基，二苯甲氧基-C.sub.1-6 -烷基，C.sub.1-8 -烷基，C.sub.4-10 -环烷基烷基，苯氧基-C.sub.1-8 -烷基或C.sub.1-6 -烷氧基-C.sub.1-6 -烷基; 而R是##STR2##或CH.dbd.NOR'，其中R'是C.sub.1-6 -烷基，C.sub.3-7 -环烷基，C.sub.1-6 -烷氧基-C.sub.1-6 -烷基，芳基-C.sub.0-6 -烷基，可以选择地用一个或多个卤素和(.sub.1-5 -烷氧基，噻吩基或C.sub.4-7 -环烷基烷基取代的。这些新的化合物用于治疗疼痛症状和作为神经类药物。

  公开号：

  US04845095A1

文献信息

• [EN] NAPHTHYL ETHER COMPOUNDS AND THEIR USE<br/>[FR] COMPOSES DE NAPHTYL ETHER ET LEUR UTILISATION
  申请人：ASTRAZENECA AB

  公开号：WO2004022539A1

  公开（公告）日：2004-03-18

  Compounds having the following structure wherein R1, R2, R3, R4, R5, R6, R7 m and n are as defined in the specification, in vivo-hydrolysable precursors thereof, pharmaceutically-acceptable salts thereof, the use in therapy and pharmaceutical compositions and methods of treatment using the same.

  具有以下结构的化合物，其中R1、R2、R3、R4、R5、R6、R7、m和n如规范中定义，其体内可水解的前体，其药用盐，以及在治疗中的使用、制药组合物和使用相同的治疗方法。
• Synthesis and biological activity of spiro(isocoumarin-piperidines) and reltaed compounds. I.
  作者：MASATOSHI YAMATO、KUNIKO HASHIGAKI、MASAO IKEDA、HIDETOSHI OHTAKE、KENJI TASAKA

  DOI：10.1248/cpb.29.402

  日期：——

  1'-Alkylspiro [isochroman-3, 4'-piperidin]-1-ones (2) and 1'-alkylspiro [isochroman-4, 4'-piperidines] (4 and 5) were prepared and examined for analgesic activity. Several of the 4-spiro compounds (3, 4, and 5) were found to have analgesic activity as potent as that of aminopyrine, while the 3-spiro compounds (2) were inactive. Further pharmacological studies revealed that several of these compounds inhibited the histamine release induced by compound 48/80 from isolated rat peritoneal mast cells.

  1'-烷基螺[异香豆素-3, 4'-哌啶]-1-酮（2）和1'-烷基螺[异香豆素-4, 4'-哌啶]（4和5）已经被合成并检查其镇痛活性。发现其中几种4-螺化合物（3、4和5）的镇痛活性与氨基吡嗪相当，而3-螺化合物（2）则无活性。进一步的药理研究表明，这些化合物中的几种抑制了由化合物48/80诱导的孤立大鼠腹膜肥大细胞释放组胺。
• Synthesis and structure-activity relationship of spiro[isochromanpiperidine] analogs for inhibition of histamine release. 1
  作者：Masatoshi Yamato、Kuniko Hashigaki、Masao Ikeda、Hidetoshi Ohtake、Kenji Tasaka

  DOI：10.1021/jm00134a013

  日期：1981.2

  ,4'-piperidines] were prepared and examined for their biological activity. Several of the compounds inhibited the compound 48/80 induced histamine release from isolated rat peritoneal mast cells. The structural requirements for this activity in the present series are discussed.

  制备了两种类型的1'-烷基螺基[isochroman-3,4-哌啶]和1'-烷基螺基[isochroman-4,4'-哌啶]并检查了它们的生物学活性。几种化合物抑制了化合物48/80诱导的组胺从分离的大鼠腹膜肥大细胞中释放。讨论了本系列中此活动的结构要求。
• Naphthyl ether compounds and their use
  申请人：Bernstein Peter

  公开号：US20050245572A1

  公开（公告）日：2005-11-03

  Compounds having the following structure wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 m and n are as defined in the specification, in vivo-hydrolysable precursors thereof, pharmaceutically-acceptable salts thereof, the use in therapy and pharmaceutical compositions and methods of treatment using the same.

  具有以下结构的化合物，其中R1、R2、R3、R4、R5、R6、R7m和n如规范中所定义，其体内可水解的前体物，其药学上可接受的盐，其在治疗中的应用以及使用其进行治疗的制药组合物和方法。
• 3-CYANO-4-(4-PHENYL-PIPERIDIN-1-YL)-PYRIDIN-2-ONE DERIVATIVES
  申请人：Cid-Núñez José Maria

  公开号：US20100063092A1

  公开（公告）日：2010-03-11

  The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) including any stereochemically isomeric form thereof, or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein all radicals are defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic glutamate receptors subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and such compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.

  本发明涉及新型化合物，特别是根据公式（I）的新型吡啶酮衍生物，包括其任何立体化异构体形式、药学上可接受的盐或其溶剂化物，其中所有基团在申请和权利要求中均有定义。本发明所述化合物是代谢型谷氨酸受体亚型2（“mGluR2”）的正向变构调节剂，可用于治疗或预防与谷氨酸功能障碍相关的神经和精神障碍以及涉及代谢型受体mGluR2亚型的疾病。特别是，这些疾病是选择自焦虑、精神分裂症、偏头痛、抑郁症和癫痫等中枢神经系统疾病的一组。本发明还涉及制备这种化合物和这种组合物的制药组合物和过程，以及将这种化合物用于预防和治疗涉及mGluR2的这种疾病。